Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

In September 2024, Checkpoint presented longer-term data from its pivotal trial of cosibelimab in locally advanced and metastatic cSCC during the European Society for Medical Oncology ("ESMO") ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

The initial data we presented at ESMO GI in 2024 just a few months ago from the Cornell study highlights this potential. These results in a tumor type, historically resistant to immunotherapy are ...

evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of patients with metastatic disease were presented at the 2024 European Society of Medical Oncology (ESMO) Congress ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...